SAN ANTONIO - bioAffinity Technologies, Inc. , a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other lung diseases, today announced that the.
bioAffinity (BIAF) Announces CMS Posts Final Payment Determination for CyPath Lung Effective January 2024 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
30.11.2023 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other lung diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) . Seite 1
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that the US Centers for Medicare & Medicaid Services has published its final determination of the national reimbursement price in the United States for the PromarkerD predictive test for diabetic kidney disease.
Proteomics International Laboratories Ltd is pleased to announce that the US Centers for Medicare & Medicaid Services has published its final determination of the national reimbursement price in the.